Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (325)	12/18/2002 7:30:48 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 1840

The Oncologist, Capitol Hill report.... The FDA’s oncology division is testing the waters for re-visiting the concept of accelerated approval regulations as they apply to oncology. The division has indicated that issues relative to the limited definition, as well as the structure of clinical development for the agents undergoing the review, need to be considered. The agency believes that it is timely to move toward an emphasis of interim analysis of a surrogate endpoint in a randomized trial rather than relying on nonrandomized phase II trials. The oncology division has granted 11 accelerated approvals through January 1, 2002, and nine of these were based on tumor response in single-arm phase II refractory cancers. They are encouraging a greater use of time to progression rather than tumor response as an endpoint for agents being evaluated under accelerated review. theoncologist.alphamedpress.org

To: Icebrg who wrote (325)	1/4/2003 9:02:39 AM
From: Icebrg	Read Replies (1) \| Respond to of 1840

There are number of interesting CaPCURE 2002 presentations (audio and slides) available at medsessions.com Program. Welcome and Introduction Howard Soule, M.D. Multimodality Imaging of Prostate Cancer Models in Living Mice Sanjiv Gambhir, M.D., Ph.D. Apoptosis-based Therapies for Prostate Cancer John Reed, M.D., Ph.D. Partnering for Progress in Prostate Cancer William Berg, M.D. A Systems Approach to Cancer: New Technologies and Computational Tools Leroy Hood, M.D., Ph.D. The Ubiquitin Proteolytic System: At the Crossroads of Apoptosis Aaron Ciechanover, M.D., D.Sc. Proteasome Inhibitors in Cancer Therapy Julian Adams, Ph.D. Calcitrion & Docetaxel in Prostate Cancer Tomasz Beer, M.D. Anti-CTLA4 in Combination with DNA Vaccines Enhances T Cell Immunity and Tumor Protection Polly Gregor, Ph.D. Comparing the Impact of Prostate and Breast Cancer in the U.S. June Chan, Sc.D. Immune Therapy for Prostate Cancer: Antigen Pulsed Dendritic Cells Eric Small, M.D. Toward Defining a Surrogate Marker for Prostate Cancer Specific Death Anthony D’Amico, M.D., Ph.D. Pathways Mediating the Growth Inhibitory Actions of Vitamin D in Prostate Cancer David Feldman, M.D. Androgen Stimulates HIF-1 Through an Autocrine EGF/P13K Dependent Pathway in LNCaP Prostate Cancer Cells Jonathan Simons, M.D. Genetic Polymorphisms and Prostate Cancer Risk Janet Stanford, Ph.D. Signal Transduction in Prostate Cancer Progression to Androgen Independence Michael Weber, Ph.D. Characterization of T Cell-Defined Antigens Expressed by Murine and Human Prostate Cancer Cells James Allison, Ph.D. Integrated Therapy of Prostate Cancer Christopher Logothetis, M.D. Androgen Receptor Signaling as a Target for Therapy in Prostate Cancer Howard Scher, M.D. Genome-Wide Studies of Gene Expression in Cancer David Botstein, M.D., Ph.D. COX-2 Inhibitors: From Inflammation to Cancer Philip Needleman, Ph.D. Accelerating Medical Solutions Michael Milken Novel Her-kinase Inhibitors & Raloxifine David Agus, M.D. Inhibitors of HSP90 Function as Cancer Therapeutics Neal Rosen, M.D., Ph.D. Mifepristone Acts as an Androgen Receptor Antagonist and Stimulates Binding of AR Corepressors Edward Gelmann, M.D. Phase II Trial of 2 methoxyestradiol in Advanced Prostate Cancer George Wilding, M.D. Bone Targeted Therapy for Prostate Cancer Matthew Smith, M.D., Ph.D. Special Session on Challenges of Curing Cancer Donald Coffey, Ph.D. Special Session on Challenges of Curing Cancer Andrew von Eschenbach, M.D. Prostate Cancer Promotion and Dietary Fat: The Role of PPAR Signaling Ronald Evans, Ph.D. GSTP1 Inactivation and Prostate Cancer Progression William Nelson, M.D., Ph.D. Identification of Clinically Relevant Activity Pathways of Complementary and Alternative Prostate Cancer Therapies Peter Nelson, M.D. Investigation of Plant-Based Diets and Caloric Restriction Effects on Prostate Cancer Cell Growth David Heber, M.D. Prostate Cancer in Native Japanese and Japanese-American Men Leonard Marks, M.D.